CISEN(603367)

Search documents
辰欣药业股价跌5.07%,天弘基金旗下1只基金重仓,持有17.04万股浮亏损失24.37万元
Xin Lang Cai Jing· 2025-08-27 06:56
Group 1 - The core point of the news is that Chenxin Pharmaceutical experienced a decline of 5.07% in its stock price, reaching 26.80 yuan per share, with a trading volume of 410 million yuan and a turnover rate of 3.30%, resulting in a total market capitalization of 12.134 billion yuan [1] - Chenxin Pharmaceutical, established on November 6, 1998, and listed on September 29, 2017, is primarily engaged in the research, development, and production of chemical drug formulations. The main revenue composition includes: small volume injectables (30.05%), large-volume infusions in plastic bottles (23.12%), large-volume infusions in non-PVC soft bags (15.02%), oral solid formulations (12.87%), large-volume infusions in glass bottles (5.53%), lyophilized powder injections (4.17%), ointments (4.16%), drops (3.36%), raw materials (self-produced and exported) (1.00%), rinsing agents (0.45%), and others (0.25%) [1] Group 2 - Tianhong Fund has one fund heavily invested in Chenxin Pharmaceutical, specifically the Tianhong Quality Growth Enterprise Selected Mixed Fund A (007202), which held 170,400 shares, accounting for 2.41% of the fund's net value, ranking as the ninth largest holding. The estimated floating loss today is approximately 243,700 yuan [2] - The Tianhong Quality Growth Enterprise Selected Mixed Fund A (007202) was established on October 18, 2019, with a latest scale of 93.4404 million yuan. Year-to-date returns are 19.17%, ranking 3914 out of 8194 in its category; the one-year return is 34.05%, ranking 4073 out of 7963; and since inception, the return is 100.49% [2]
辰欣药业(603367)8月25日主力资金净流入5042.98万元
Sou Hu Cai Jing· 2025-08-25 09:01
金融界消息 截至2025年8月25日收盘,辰欣药业(603367)报收于29.51元,上涨3.04%,换手率 3.65%,成交量16.50万手,成交金额4.88亿元。 资金流向方面,今日主力资金净流入5042.98万元,占比成交额10.33%。其中,超大单净流入1531.71万 元、占成交额3.14%,大单净流入3511.27万元、占成交额7.19%,中单净流出流出2642.88万元、占成交 额5.41%,小单净流出2400.10万元、占成交额4.92%。 通过天眼查大数据分析,辰欣药业股份有限公司共对外投资了18家企业,参与招投标项目5000次,知识 产权方面有商标信息230条,专利信息288条,此外企业还拥有行政许可609个。 来源:金融界 辰欣药业最新一期业绩显示,截至2025一季报,公司营业总收入9.20亿元、同比减少19.91%,归属净利 润1.44亿元,同比减少11.86%,扣非净利润1.16亿元,同比减少19.66%,流动比率3.540、速动比率 2.983、资产负债率19.23%。 天眼查商业履历信息显示,辰欣药业股份有限公司,成立于1998年,位于济宁市,是一家以从事医药制 造业为主的企业。 ...
化学制药板块8月25日涨2.53%,舒泰神领涨,主力资金净流出4.26亿元
Zheng Xing Xing Ye Ri Bao· 2025-08-25 08:47
Group 1 - The chemical pharmaceutical sector increased by 2.53% on August 25, with Shutaishen leading the gains [1] - The Shanghai Composite Index closed at 3883.56, up 1.51%, while the Shenzhen Component Index closed at 12441.07, up 2.26% [1] - Notable gainers in the chemical pharmaceutical sector included: - Buzoushen (300204) with a closing price of 61.00, up 16.17% and a trading volume of 445,500 shares [1] - Haichen Pharmaceutical (300584) with a closing price of 58.95, up 13.61% and a trading volume of 217,200 shares [1] - Changshan Pharmaceutical (300255) with a closing price of 53.25, up 12.84% and a trading volume of 683,900 shares [1] Group 2 - The chemical pharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 509 million yuan [2] - The top stocks by net inflow from retail investors included: - Anglikang (002940) with a net inflow of 163 million yuan, representing 22.87% of its trading volume [3] - Haichen Pharmaceutical (300584) with a net inflow of 132 million yuan, representing 10.90% of its trading volume [3] - Lingkang Pharmaceutical (603669) with a net inflow of 64.68 million yuan, representing 37.53% of its trading volume [3]
辰欣药业精心设计的股权游戏:前任管理层三步走实现“清仓式”减持
Xin Lang Zheng Quan· 2025-08-22 09:04
炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 2024年5月,南京辰昕将4541.3834万股股份转让给韩延振,转让价格14.94元/股。至此不难发现,辰欣 药业前任管理层中,除韩延振之外,其余各管理层均已完成套现离场,韩延振则通过个人主体完成最后 的于二级市场进行的减持。 沪指乘风破浪,接连刷新高点,成功站上3700点大关,市场情绪一片火热。然而,与指数"高歌猛进"形 成微妙对比的是,上市公司重要股东减持公告正悄然增多。据统计,8月1日至今,沪深两市已有超过30 家生物医药上市公司发布了股东减持计划,其中减持比例大于或等于3%的公司如下图所示。 | 公告时间 | 公司 | 駆持主体 | 糖持股数(万股) | 球持股数占总股 本比例 | | --- | --- | --- | --- | --- | | 8月7日 | 力诺药包 | 5%以上股东、高管 | 840.73 | 3.61% | | 8月4日 | 康泰医学 | 5%以上股东、高管 | 1441.6 | 3.59% | | 8月14日 | 声音美斯 | 5%以上股东、5%以下股东 | 509.45 | 3.04% | | 8 ...
化学制药板块8月20日跌0.27%,福元医药领跌,主力资金净流出34.16亿元
Zheng Xing Xing Ye Ri Bao· 2025-08-20 08:41
从资金流向上来看,当日化学制药板块主力资金净流出34.16亿元,游资资金净流入3.43亿元,散户资金 净流入30.73亿元。化学制药板块个股资金流向见下表: | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 601089 | 福元医药 | 27.72 | -10.00% | 24.51万 | | 7.02亿 | | 603811 | 诚意药业 | 15.14 | -9.99% | 55.02万 | | 8.63亿 | | 603367 | 辰欣药业 | 30.65 | -9.99% | 23.75万 | | 7.59亿 | | 002940 | 昂利康 | 49.45 | -9.86% | 16.65万 | | 8.47 亿 | | 300436 | 广生堂 | 146.90 | -8.69% | 17.06万 | | 25.93 Z | | 300016 | 北陆药业 | 10.32 | -8.35% | 98.85万 | | 10.50亿 | | 300558 | 贝达药业 | ...
辰欣药业上涨7.75%,报33.94元/股
Jin Rong Jie· 2025-08-15 03:27
Core Viewpoint - The stock price of Chenxin Pharmaceutical increased by 7.75% on August 15, reaching 33.94 CNY per share, with a trading volume of 448 million CNY and a turnover rate of 3.05%, resulting in a total market capitalization of 15.366 billion CNY [1] Company Overview - Chenxin Pharmaceutical Co., Ltd. is located in Jining High-tech Zone, Tongji Technology Industrial Park, and is a comprehensive pharmaceutical enterprise engaged in research and development, production, and sales [1] - The company focuses on independently developing and producing drugs that fill domestic gaps, investing 6% of its annual sales revenue into scientific research [1] - Successful drug developments include Adefovir Dipivoxil, and the company has established long-term cooperative relationships with several research institutions [1] Financial Performance - For the period from January to March 2025, Chenxin Pharmaceutical reported operating revenue of 920 million CNY, a year-on-year decrease of 19.91% [1] - The net profit attributable to shareholders was 144 million CNY, reflecting a year-on-year decrease of 11.86% [1] - As of March 31, the number of shareholders was 21,400, with an average of 21,200 circulating shares per person [1]
辰欣药业股价回调3.67% 化学制药板块成交额达8.54亿元
Jin Rong Jie· 2025-08-13 21:26
Group 1 - As of August 13, 2025, the stock price of Chenxin Pharmaceutical is 32.24 yuan, down 1.23 yuan from the previous trading day, with a trading range of 6.42% [1] - The opening price on the same day was 33.66 yuan, reaching a high of 33.85 yuan and a low of 31.70 yuan, with a trading volume of 263,594 hands and a total transaction amount of 854 million yuan [1] - The company is located in Shandong Province and is a significant pharmaceutical manufacturer in the region, focusing on drug research, production, and sales [1] Group 2 - On August 13, during the early trading session, Chenxin Pharmaceutical experienced a rapid decline, with a drop of over 2% within the first five minutes before 9:35 AM, and a transaction amount of 64.79 million yuan at that time [1] - The net outflow of main funds on that day was 132.35 million yuan, with a cumulative net outflow of 158.95 million yuan over the past five trading days [1] - The company's product line includes anti-infection drugs, cardiovascular drugs, and digestive system drugs, covering multiple therapeutic areas [1]
中证腾讯济安价值100A股指数上涨0.52%,前十大权重包含辰欣药业等
Jin Rong Jie· 2025-08-11 15:42
Core Points - The CSI Tencent Ji'an Value 100 A-Share Index has shown significant growth, with a 6.92% increase over the past month, 13.78% over the past three months, and 14.10% year-to-date [1] - The index is composed of 100 listed companies selected based on their investment value assessments by Tencent and Ji'an Jinxin's evaluation committee [1] - The index's top ten holdings include Huaguang Huaneng (1.94%), Chenxin Pharmaceutical (1.92%), and Taotao Automotive (1.8%) among others [1] Market Composition - The CSI Tencent Ji'an Value 100 A-Share Index is primarily composed of stocks from the Shanghai Stock Exchange (64.71%) and Shenzhen Stock Exchange (35.29%) [1] - The industry distribution of the index shows that Industrial sector holds 27.80%, Consumer Discretionary 17.84%, and Materials 12.44% among others [2] Index Management - The index samples are adjusted biannually, with changes implemented on the next trading day after the second Friday of June and December [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes significant corporate changes [2] Fund Tracking - Public funds tracking the CSI Tencent Ji'an include the Galaxy Regular Investment Fund [3]
流感概念下跌1.41%,主力资金净流出137股
Zheng Quan Shi Bao Wang· 2025-08-06 08:30
Group 1 - The flu concept sector experienced a decline of 1.41%, ranking among the top declines in concept sectors, with companies like Qizheng Pharmaceutical and Hanyu Pharmaceutical seeing significant drops [1][2] - Among the 22 stocks that rose, Hotgen Biotech, Borui Pharmaceutical, and Chenxin Pharmaceutical led with increases of 10.97%, 9.96%, and 8.16% respectively [1][2][8] Group 2 - The flu concept sector saw a net outflow of 3.988 billion yuan, with 137 stocks experiencing net outflows, and 7 stocks seeing outflows exceeding 100 million yuan [2] - Hanyu Pharmaceutical had the highest net outflow of 256 million yuan, followed by Tonghua Jinma and Zhendong Pharmaceutical with outflows of 159 million yuan and 153 million yuan respectively [2][3] - Stocks with the highest net inflows included Borui Pharmaceutical, Chenxin Pharmaceutical, and Xiangrikui, with inflows of 222 million yuan, 121 million yuan, and 3.468 million yuan respectively [2][8]
A股婴童股普涨,奇德新材涨8%辰欣药业涨7%,海伦钢琴涨5%!免除公办幼儿园学前一年保教费+3周岁以下婴幼儿每孩每年发3600元
Ge Long Hui· 2025-08-06 04:13
Core Viewpoint - The A-share market for baby and child-related stocks experienced a significant increase, driven by recent government policies aimed at promoting early childhood education and providing financial support for families with young children [1][2]. Group 1: Stock Performance - Qide New Materials (300995) saw an increase of 8.47%, with a total market value of 3.956 billion and a year-to-date increase of 198.59% [2]. - Chenxin Pharmaceutical (603367) rose by 7.29%, with a market capitalization of 14.6 billion and a year-to-date increase of 138.23% [2]. - Helen Piano (300329) increased by 5.64%, with a market value of 3.219 billion and a year-to-date increase of 149.00% [2]. - Hejing Technology (300279) grew by 4.95%, with a market capitalization of 3.942 billion and a year-to-date increase of 33.00% [2]. - Chuangyuan Co. (300703) rose by 4.36%, with a market value of 4.365 billion and a year-to-date increase of 71.09% [2]. - Beingmate (002570) increased by 4.24%, with a market capitalization of 7.971 billion and a year-to-date increase of 75.30% [2]. - Angli Education (600661) saw a rise of 3.95%, with a market value of 3.393 billion and a year-to-date increase of 1.02% [2]. Group 2: Government Policies - The State Council issued an opinion on August 5 to gradually implement free preschool education, starting from the fall semester of 2025, which will waive the care and education fees for children in public kindergartens [2]. - A new implementation plan for a childcare subsidy system was released on July 28, which will provide cash subsidies to families with children under three years old, starting from January 1, 2025. The current basic standard for the subsidy is 3,600 yuan per child per year [2].